$0.25
72.53% yesterday
Nasdaq, Jul 23, 09:29 pm CET
ISIN
US89532E1091
Symbol
TRVN

Trevena, Inc. Stock price

$0.91
-0.19 17.27% 1M
-0.78 46.15% 6M
-0.59 39.33% YTD
-4.74 83.89% 1Y
-168.72 99.46% 3Y
-1,205.34 99.92% 5Y
-4,249.09 99.98% 10Y
-4,061.59 99.98% 20Y
Nasdaq, Closing price Wed, Jul 23 2025
+0.00 0.00%
ISIN
US89532E1091
Symbol
TRVN
Industry

Key metrics

Basic
Market capitalization
$790.0k
Enterprise Value
$20.2m
Net debt
$19.4m
Cash
$13.5m
Shares outstanding
850.0k
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.2 | 1.2
EV/Sales
5.4 | 31.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-18.9%
Return on Equity
526.2%
ROCE
-437.0%
ROIC
-
Debt/Equity
-1.4
Financials (TTM | estimate)
Revenue
$3.8m | $640.6k
EBITDA
$-56.9m | -
EBIT
$-57.2m | $-25.1m
Net Income
$-57.8m | $-20.0m
Free Cash Flow
$-27.1m
Growth (TTM | estimate)
Revenue
16.8% | -79.5%
EBITDA
-66.5% | -
EBIT
-65.9% | 28.9%
Net Income
-87.8% | 50.4%
Free Cash Flow
28.2%
Margin (TTM | estimate)
Gross
47.4%
EBITDA
-1,515.9% | -
EBIT
-1,525.3%
Net
-1,540.0% | -3,118.5%
Free Cash Flow
-721.9%
More
EPS
$-67.8
FCF per Share
$-31.9
Short interest
7.0%
Employees
23
Rev per Employee
$140.0k
Show more

Is Trevena, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,026 stocks worldwide.

Trevena, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Trevena, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Trevena, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Trevena, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.75 3.75
17% 17%
100%
- Direct Costs 1.98 1.98
214% 214%
53%
1.78 1.78
31% 31%
47%
- Selling and Administrative Expenses 34 34
57% 57%
899%
- Research and Development Expense 25 25
63% 63%
674%
-57 -57
66% 66%
-1,517%
- Depreciation and Amortization 0.36 0.36
9% 9%
10%
EBIT (Operating Income) EBIT -57 -57
66% 66%
-1,527%
Net Profit -58 -58
88% 88%
-1,541%

In millions USD.

Don't miss a Thing! We will send you all news about Trevena, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Head office United States
CEO Carrie Bourdow
Employees 23
Founded 2007
Website www.trevena.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today